Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Share-based Compensation: 2010-2021

Historic Share-based Compensation for Neurocrine Biosciences (NBIX) over the last 11 years, with Dec 2021 value amounting to $35.6 million.

  • Neurocrine Biosciences' Share-based Compensation rose 69.52% to $35.6 million in Q4 2021 from the same period last year, while for Dec 2021 it was $134.2 million, marking a year-over-year increase of 34.20%. This contributed to the annual value of $195.5 million for FY2024, which is 0.62% up from last year.
  • Neurocrine Biosciences' Share-based Compensation amounted to $35.6 million in Q4 2021, which was down 4.04% from $37.1 million recorded in Q3 2021.
  • In the past 5 years, Neurocrine Biosciences' Share-based Compensation registered a high of $37.1 million during Q3 2021, and its lowest value of $9.0 million during Q1 2017.
  • For the 3-year period, Neurocrine Biosciences' Share-based Compensation averaged around $25.8 million, with its median value being $24.8 million (2020).
  • As far as peak fluctuations go, Neurocrine Biosciences' Share-based Compensation soared by 121.47% in 2018, and later declined by 20.52% in 2019.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' Share-based Compensation stood at $13.5 million in 2017, then dropped by 1.13% to $13.3 million in 2018, then surged by 60.15% to $21.3 million in 2019, then fell by 1.41% to $21.0 million in 2020, then spiked by 69.52% to $35.6 million in 2021.
  • Its Share-based Compensation stands at $35.6 million for Q4 2021, versus $37.1 million for Q3 2021 and $28.6 million for Q2 2021.